



2019 MPA Spring Seminar

April 26th-27th, 2019

An offering of the MPA Health-Systems Academy

Mansfield Health Education Center, St. Vincent Healthcare - Billings
Skaggs School of Pharmacy, University of Montana - Missoula

PO Box 1569 Helena, MT 59624 406-449-3843 info@rxmt.org



ACPE Approval: Attendance at all sessions will provide 9.75 contact hours / 0.975 CEU for pharmacists and 6.0 contact hours / 0.6 CEU for pharmacy technicians although learning objectives may vary on some presentations. There are 5 modules. Participants must attend all sessions in a module to receive the credit for that module.

The overall learning objectives of the conference are:

1. to provide evidence-based information / education and emerging practices in the field of pharmacology that enhances professional knowledge, and
2. to provide up-to-date information in pharmaceutical health care that professionals can share with clients.

Friday – April 26, 2019

1:00 – 2:00 pm

Conference call
Billings⇒Missoula

Montana Pharmacist Patient Care Alliance Meeting

Carla Cobb, PharmD, BCPP – Owner, Capita Consulting, Billings
(Registration not required to participate in this meeting. Not ACPE approved.)

2:00 – 2:30 pm

Registration

2:30 – 2:45 pm

Welcome, Announcements, and Pre-Test Questions

Module 1 (2:45 – 4:10pm and 5:15-6:35pm): Approved for 2.5 contact hours / 0.25 CEU for pharmacists. Must be present for entire module to receive credit. Partial credit for module is not available. **UAN: #0035-9999-19-018-L01-P.**

2:45 – 3:05 pm

Missoula⇒Billings

Implementation of a clinical pharmacist driven medication therapy management program for uncontrolled hypertension and cholesterol

Demi Cole, PharmD; PGY1 Pharmacy Resident; Community Medical Center, Missoula

At the close of this presentation, pharmacists will be able to:

1. Identify the impact pharmacy led intervention has on chronic disease state management, specifically hypertension and hypercholesterolemia.

3:05 – 3:25 pm

Missoula⇒Billings

Impact of an ambulatory care pharmacist in psychiatric patient care

Kellie Forrest, PharmD; PGY1 Pharmacy Resident; St. Peter's Hospital, Helena

At the close of this presentation, pharmacists will be able to:

1. Recognize psychiatric patients who may benefit from a pharmacist driven ambulatory care visit regarding metabolic management, medication intervention, and education based on the recommendations from national guidelines.
2. Identify metabolic disturbances related to second-generation antipsychotics (SGAs).

3:25 – 3:45 pm

Missoula⇒Billings

Standardized referral of at-risk hospitalized patients for pharmacist-driven comprehensive medication management in a comprehensive primary care plus clinic: analysis of 30-day hospital readmissions.

Cory Lovec, PharmD; PGY1 Pharmacy Resident; Billings Clinic, Billings

At the close of this presentation, pharmacists will be able to:

1. Compare rates of 30-day hospital readmissions and emergency department visits before and after implementation of a standardized referral of patients to ambulatory pharmacist-led comprehensive medication management (CMM).
2. Describe strengths and weakness of the standardized CMM referral process.

3:45 – 4:05 pm
Missoula⇒Billings

Automated referral to an ambulatory care pharmacist for patients recently hospitalized with chronic obstructive pulmonary disease exacerbation: impact on 30-day hospital readmissions

Kiarra McGee, PharmD; PGY1 Pharmacy Resident; Billings Clinic, Billings

At the close of this presentation, pharmacists will be able to:

1. List the most common drug therapy problems identified by providers versus pharmacists in patients with a recent COPD exacerbation.
2. Discuss strengths and weaknesses of the standardized COPD referral process.

4:05 - 4:10 pm **Break**

Non- Resident Session 1

Module 2 (4:10 – 5:10pm): Approved for 1.0 contact hours / 0.1 CEU for pharmacists and pharmacy technicians.

UAN: #0035-9999-19-019-L04-P/T

4:10 – 5:10 pm
Billings⇒Missoula

Payment for Pharmacist-Provided Patient Care Services in Montana

Carla Cobb, PharmD, BCPP; Clinical Pharmacist Specialist, Psychiatry; Riverstone Health, Billings

At the close of this presentation, pharmacists will be able to:

1. List the requirements to become a board-certified pharmacist and a clinical pharmacist practitioner (CPP) in Montana.
2. Describe the process to become credentialed with Montana healthcare payers.
3. Discuss some of the challenges and successes of payment for pharmacists' services

At the close of this presentation, pharmacy technicians will be able to:

1. List the requirements to become a board certified pharmacist and a clinical pharmacist practitioner (CPP) in Montana.
2. Describe the process to become credentialed with Montana healthcare payers.
3. Discuss some of the challenges and successes of payment for pharmacists services.

5:10 – 5:15 pm **Break**

Pharmacy Resident Project Presentations II

5:15 – 5:35 pm
Missoula⇒Billings

Impact of changing from weight-based to standard dosing of continuous intravenous fentanyl infusion on overall fentanyl utilization in a medical-surgical intensive care unit

Elizabeth Klein, PharmD; PGY1 Pharmacy Resident; Billings Clinic, Billings

At the close of this presentation, pharmacists will be able to:

1. Discuss overall fentanyl utilization when using weight-based dosing (mcg/kg/hr) versus standard dosing (mcg/hr) in ICU patients.
2. Describe the differences in pain scores and additional opioid use in patients receiving weight-based versus standard dosing of continuous IV fentanyl infusions.

5:35 – 5:55 pm
Billings⇒Missoula

Ceftriaxone monotherapy versus ceftriaxone plus azithromycin for the treatment of community acquired pneumonia in inpatient non-ICU patients

Forrest Murter, PharmD; PGY1 Pharmacy Resident; St. Vincent Healthcare, Billings

At the close of this presentation, pharmacists will be able to:

1. Compare ceftriaxone monotherapy to ceftriaxone in combination with azithromycin for the treatment of community acquired pneumonia.

5:55 – 6:15 pm Billings⇒Missoula	<p>Implementation of ICU bundles and the impact on pain, agitation, and delirium in critically ill patients in the ICU</p> <p>Rachel Moore, PharmD; PGY1 Pharmacy Resident; St. Peter’s Hospital, Helena</p> <p>At the close of this presentation, pharmacists will be able to:</p> <ol style="list-style-type: none"> 1. Formulate an optimal medication regimen of sedation and analgesia, including starting doses and titration parameters, for a ventilated patient using a hospital protocol. 2. Describe the observational components needed to calculate RASS, CPOT, and CAM-ICU scores, and be able to titrate sedation and analgesia given a calculated RASS or CPOT score.
6:15 –6:35 pm Billings⇒Missoula	<p>A retrospective cohort study comparing activated partial thromboplastin time versus anti-factor Xa for therapeutic monitoring of unfractionated heparin</p> <p>Sarah Wheeler, PharmD; PGY1 Pharmacy Resident; St. Vincent Healthcare, Billings</p> <p>At the close of this presentation, pharmacists will be able to:</p> <ol style="list-style-type: none"> 1. Describe the differences in heparin monitoring and management.
6:35 – 7:00 pm	Post-Test Questions and Evaluations
7:00 – 8:00 pm	Reception

Saturday – April 27, 2019

8:00 – 8:30 am	Registration and Continental Breakfast
8:30 – 8:45 am	Welcome, Announcements and Pre-Test Questions

Module 3 (8:45 – 11:55 am): *Approved for 3.0 contact hours / 0.3 CEU for pharmacists and pharmacy technicians. Must be present for entire module to receive credit. Partial credit for module is not available. UAN: #0035-9999-19-20-L01-P/T*

Non-Resident Session II

8:45 – 9:45 am Billings⇒Missoula	<p>Anticoagulation Clinical Pearl Session</p> <ul style="list-style-type: none"> • Effective preoperative management of patients on anticoagulants • Anticoagulation reversal in the era of the non-vitamin K oral anticoagulants <p>Logan Tinsen, Pharm.D. Benefis Hospitals and Emily Steed Doctor of Pharmacy, Benefis Hospitals</p> <p>At the close of this presentation, pharmacists will be able to</p> <ol style="list-style-type: none"> 1. Compare and contrast the available agents for emergent reversal of oral anticoagulants. 2. Discuss the pros and cons of adding Andexxa® (andexanet alfa) to formulary. <p>At the close of this presentation, pharmacy technicians will be able to</p> <ol style="list-style-type: none"> 1. Explain how to assist in medication procurement and sterile compounding of anticoagulation reversal agents.
9:45 –10:45 am Missoula⇒Billings	<p>An Update on Antimicrobial Stewardship in Montana</p> <p>Jenner Minto, PharmD, Department of Pharmacy Practice, Skaggs School of Pharmacy, University of Montana, Erika Baldry, MPH, epidemiologist with Department of Public Health and Human Services, Helena, MT, Jeff Jansen, PharmD, infectious disease Saint Vincent Hospital, Billings, MT</p> <p>At the close of this presentation, pharmacists will be able to:</p> <ol style="list-style-type: none"> 1. Recognize the negative impact of a reported penicillin allergy on patients and health systems. 2. Evaluate a patient’s penicillin allergies for accuracy. 3. Describe the different Healthcare-Associated Infection (HAI) data utilized for data-driven interventions related to HAIs and Antimicrobial Stewardship (AMS) in Montana. 4. Identify areas of collaboration between Public Health and Pharmacy to improve Antimicrobial Stewardship (AMS) in Montana.

5. Recognize challenges associated with collection and analysis of statewide Antimicrobial Stewardship data.

At the close of this presentation, pharmacy technicians will be able to:

1. Recognize the negative impact of a reported penicillin allergy on patients and health systems.
2. Identify areas of collaboration between Public Health and Pharmacy to improve Antimicrobial Stewardship (AMS) in Montana.
3. Recognize the importance of Antimicrobial Stewardship programs.

10:45– 10:55 am Break

Resident Project Presentation III

10:55 – 11:15 am Evaluating compliance with current guidelines for diagnosis and treatment of clostridium difficile infections in a community hospital
Missoula⇒Billings

Emily Kardash, PharmD; PGY1 Pharmacy Resident; Community Medical Center, Missoula

At the close of this presentation, pharmacists will be able to:

1. Describe first line treatment options for *Clostridioides difficile*.
2. Identify risk factors associated with *Clostridioides difficile* infections.

At the close of this presentation, technicians will be able to:

1. Recognize why treatment proper treatment of *Clostridioides difficile* is important.
2. State proper procedures of oral vancomycin compounding.

11:15 – 11:35 am Prescribing potentially inappropriate medications in the elderly related to fall risks: Need for a deprescribing guideline
Missoula⇒Billings

Malte Breitlow, PharmD; PGY1 Pharmacy Resident; Bozeman Health Deaconess Hospital, Bozeman

At the close of this presentation, pharmacists will be able to:

1. Describe the principles of deprescribing along with prioritizing a plan for a regimen.
2. Evaluate a patient’s medication list and be able to identify inappropriate prescribing.

At the close of this presentation, technicians will be able to:

1. Describe how elderly patients are at risk for falls related to medications.

11:35 – 11:55 am Assessing the effects education, guidelines and dosing aids have on the safety, efficiency, and confidence in medication dosing during pediatric emergency events
Missoula⇒Billings

Rachael Hendricks, PharmD; PGY1 Pharmacy Resident; Bozeman Health Deaconess Hospital, Bozeman

At the close of this presentation, pharmacists will be able to:

1. Describe the impact that education, guidelines, and dosing aids have on confidence, safety, efficacy and overall quality of care during pediatric medical emergencies.
2. Identify risks in medication dosing during pediatric emergency events.

At the close of this presentation, technicians will be able to:

1. Describe the importance of properly stocking and storing medications used for pediatric emergencies.

11:55 – 12:10 pm Grab and Go Lunch

Module 4 (12:10 – 2:10pm): Approved for 2.0 contact hours / 0.20 CEU for pharmacists and pharmacy technicians. Must be present for entire module to receive credit. Partial credit for module is not available. UAN: #0035-9999-19-021-L04-P/T

12:10– 1:40 pm Supporting our Own: Building Awareness, Support, and Resilience in Healthcare

Missoula⇒Billings
Megan Hamilton, MSN, RN, CFRN, NR-Paramedic

At the close of this presentation, pharmacists and pharmacy technicians will be able to:

1. Define terminology (critical incident, second victim phenomenon), sources of stress, and reactions to stress that impact the healthcare professional personally and professionally.
2. List at least two strategies to build personal and team resilience that you can apply to your own practice.

1:40 – 2:10 pm
Billings⇒Missoula

MT ASHP House of Delegates Update

Jason Nickisch, PharmD, MBA, BCPS; Director of Pharmacy; Providence St. Patrick Hospital, Missoula
Jeffery Ferber, PharmD; Medication Safety Officer; Billings Clinic, Billings

At the close of this presentation, pharmacists and pharmacy technicians will be able to:

1. Describe the proposed policies being considered by the 2019 ASHP House of Delegates.

2:10 – 2:20 Break

Module 5 (2:20-3:40): Approved for 1.25 contact hours / 0.12 for pharmacists. Not approved for pharmacy technicians. Must be present for entire module. Partial credit for module is not available. UAN: #0035-9999-19-022-L01-P

2:20 – 2:40 pm
Billings⇒Missoula

Assessing feasibility and impact of a pharmacist-managed Hepatitis B clinic within VA Montana

Michael Gantz, PharmD; PGY1 Pharmacy Resident; Montana VA Health Care System, Helena

At the close of this presentation, pharmacists will be able to:

1. List the four main components of a Hepatitis B antibody panel.
2. Discuss Heplisav-B (Hepatitis B vaccine – recombinant) and any role in current vaccination protocols.

2:40 – 3:00 pm
Billings⇒Missoula

Outcomes of a pharmacist managed outpatient benzodiazepine taper clinic at a Veterans Affairs Medical Center

Mary Mikeson, PharmD; PGY1 Pharmacy Resident; Montana VA Health Care System, Helena

At the end of this presentation, pharmacists will be able to:

1. Discuss the risks of chronic benzodiazepine use.
2. Recognize the impact of a pharmacist managed outpatient benzodiazepine taper clinic on patient care.

3:00 – 3:20 pm
Billings⇒Missoula

Urinary tract infections: Optimizing inpatient therapy

Tucker Taufou, PharmD; PGY1 Pharmacy Resident; Providence St. Patrick Hospital, Missoula

At the close of this presentation, pharmacists will be able to:

1. Develop appropriate antimicrobial regimens for urinary tract infections based on patient-specific factors.

3:20 – 3:40 pm
Billings⇒Missoula

Assessment of a pharmacy-led transitions of care discharge service in high readmission risk patients under medical resident care

Liliya Vorobey, PharmD; PGY1 Pharmacy Resident; Providence St. Patrick Hospital, Missoula

At the close of this presentation, pharmacists will be able to:

1. Describe the importance of discharge medication reconciliation and education in patients undergoing transitions of care, specifically in patients being discharged from the inpatient setting.

3:40 – 3:50 pm Post-test Questions, Evaluations, Closing Remarks

3:50 pm Adjourn



CE Info: Skaggs School of Pharmacy at the University of Montana is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based program is targeted to pharmacists and pharmacy technicians. Presentations listed in this program have been approved for ACPE continuing education credit as indicated. Upon successful completion of the verification of continuing education activity / signature sheet and program evaluation form, continuing education credits will be uploaded to the CPE Monitor within 60 days after the program.

Disclosure of Potential Conflicts of Interest: Skaggs School of Pharmacy at the University of Montana did not receive payment or services from a third party for any aspect of this activity and has no relationships (financial or other) with entities or activities that could be perceived to influence or that give the appearance of potentially influencing any portion of this activity. CE contact info: 406-243-4137 or pharmacy.ce@umontana.edu